Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ACXP
ACXP logo

ACXP News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

ACXP News

Acurx Pharmaceuticals Enters Stock Purchase Agreement

4d agoseekingalpha

Acurx Pharmaceuticals Renews Media Partnership with New to The Street

Apr 07 2026Yahoo Finance

Acurx Secures New Patent to Strengthen IP Portfolio

Mar 30 2026PRnewswire

Acurx Secures New Patent to Strengthen IP Portfolio

Mar 30 2026Newsfilter

Acurx Pharmaceuticals Q4 2025 Earnings Call Highlights

Mar 13 2026seekingalpha

Acurx Pharmaceuticals Reports Q4 Loss, Shares Drop

Mar 13 2026Benzinga

Acurx Pharmaceuticals Reports 2025 Financial Highlights

Mar 13 2026PRnewswire

Acurx Pharmaceuticals Reports 2025 Financial Results and Clinical Advances

Mar 13 2026Newsfilter

ACXP Events

04/16 08:10
Acurx Issues 825,085 Shares at $3.03 Each
Acurx announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 825,085 shares of its common stock at a purchase price of $3.03 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the company will issue unregistered short-term warrants to purchase up to 1,650,170 shares of common stock. The short-term warrants will have an exercise price of $2.78 per share, will be immediately exercisable upon issuance and will expire twenty-four months following the effective date of the registration statement registering the resale of the shares of common stock underlying the short-term warrants. The closing of the offering is expected to occur on or about April 16, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
04/07 09:30
New to The Street Renews Strategic Partnership with Acurx Pharmaceuticals
New to The Street announces the re-signing of Acurx Pharmaceuticals. The renewed agreement extends a multi-year strategic media partnership between New to The Street and Acurx, continuing a multi-platform campaign that includes long-form television interviews, outdoor billboard placements, and exclusive investor events.

ACXP Monitor News

Acurx Pharmaceuticals Announces Clinical Trial for Ibezapolstat

Mar 19 2026

Acurx Pharmaceuticals Reports Financial Highlights and Clinical Advances

Mar 17 2026

Acurx Pharmaceuticals Reports Financial Highlights and Clinical Trial Progress

Mar 16 2026

Acurx Pharmaceuticals Advances Ibezapolstat to Phase 3 Trials

Mar 13 2026

Acurx Advances CDI Patient Program to Phase 3 Trials

Mar 11 2026

Acurx Pharmaceuticals Advances to Phase 3 Trials for CDI Treatment

Mar 10 2026

Acurx Advances CDI Patient Program to Phase 3 Trials

Mar 09 2026

Acurx Pharmaceuticals Inc Surges Amid Market Decline

Dec 08 2025

ACXP Earnings Analysis

No Data

No Data

People Also Watch